ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 429

The Potential Clinical Relevance of Imaging Biomarker Data from Short-Term Interventional Trials in Osteoarthritis: A Comparison of the Cathepsin K Inhibitor Miv-711 Phase 2a MRI Knee Joint Data and KL-Matched 5577 Knee Control Data from the Osteoarthritis Initiative

Philip G. Conaghan1, Michael A Bowes2, Sarah R. Kingsbury1, Alan Brett2, Gwenael Guillard2, Åsa Jansson3, Cecilia Wadell3, Richard Bethell3 and John Öhd3, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, United Kingdom, Leeds, United Kingdom, 2Imorphics Ltd, Manchester, United Kingdom, 3Medivir AB, Huddinge, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: cathepsin k inhibitor and osteoarthritis, DMOAD, MRI

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Osteoarthritis – Clinical Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:
New imaging biomarkers using supervised machine learning offer opportunities to demonstrate effects of potential DMOADs on joint structure in short, small trials based on superior reliability. MIV-711, a cathepsin K inhibitor, demonstrated substantial effects vs placebo on both joint bone area and cartilage thickness following 6 months’ treatment. The Osteoarthritis Initiative (OAI) provides an opportunity to contextualize the short-term interventional trial data against a large prospective cohort.

Methods:
In the MIV-711-201 study (ACR 2017, abstract 14L), patients with ACR knee OA, KL2-3 and pain ≥4 & <10 on 0-10 NRS were enrolled at 6 European sites and randomised to receive MIV-711 100mg or 200mg or matched placebo qd for 6 months. 244 participants were enrolled, 69% women, mean age 62, mean BMI ~32, (evaluable for imaging; 100mg n=72, 200mg n=71, placebo n=68). 3D bone area of the medial femoral condyle (MF) and cartilage thickness in the central medial femur (cMF) were measured using automated segmentation of MR images and active appearance modelling. Rates of change were compared against annual change from all knees with KL grade 0 (normal), 2 or 3 from the OAI cohort using the same method (n =2789, 1870, 918 for KL0,2,3; 3333 patients in total).

Results:
In the MIV-711-201 quantitative MRI data, mean changes in MF bone area (mm2) were 13.4 (7.48, 19.28); 7.54 (-1.19, 16.27); 2.22 (-3.92, 8.37) for the placebo, 100mg and 200mg groups respectively (95% CI, Figure 1a). cMF cartilage thickness (mm) mean changes were -0.042 (0.001, -0.085), -0.008 (0.034,-0.051), -0.007 (0.044,-0.058) for the placebo, 100mg and 200mg respectively (95% CI, Figure 1b). These data are in good agreement with the corresponding published data based on manual segmentation. OAI MF bone area change (mm2) over 12 months was 4.26, 9.177, 20.09 (mm2) for KL0, 2 and 3 respectively (equates to 2.13, 4.59, 10.05 over 6 months assuming linear change, Figure 1c).  OAI cMF cartilage change over 12 months was -0.005, -0.024,-0.060 (mm) for KL0, 2 and 3 respectively (equates to -0.0025, -0.012, -0.03 over 6 months assuming linear change, Figure 1d).The MIV-711 placebo group changes in bone and cartilage were similar to that expected for a group of KL3 knees (OAI). The MF bone area rate of change in the 200mg group was comparable to the rate found in OAI normal (KL 0) knees and both the 100mg and 200mg doses reduced cartilage loss area change by around 80% to a rate comparable to that seen in OAI normal knees.

Conclusion:
This comparison strongly suggests that the 6-month MIV-711 treatment effects found on cartilage and bone measures has structural relevance when compared to the natural progression seen over 12 months in OAI KL3 patients.

Should such beneficial structural effects be maintained over time, the already observed signals on clinical symptoms could become manifest clinical benefits.

 


Disclosure: P. G. Conaghan, Medivir AB, 5,Novartis Pharmaceutical Co., 5,Flexion Therapeutics, 5,Abbvie, 5,Infirst, 5,Merck Serono, 5,ONO Pharmaceutical Co., 5,Galapagos, 5,GlaxoSmithKline, 5; M. A. Bowes, Imorphics Ltd, 3; S. R. Kingsbury, None; A. Brett, Stryker Corporation, 1, 3; G. Guillard, Imorphics Ltd., 3; Å. Jansson, Medivir AB, 1, 3; C. Wadell, Medivir AB, 1, 3; R. Bethell, Medivir AB, 1, 3; J. Öhd, Medivir AB, 1, 3.

To cite this abstract in AMA style:

Conaghan PG, Bowes MA, Kingsbury SR, Brett A, Guillard G, Jansson Å, Wadell C, Bethell R, Öhd J. The Potential Clinical Relevance of Imaging Biomarker Data from Short-Term Interventional Trials in Osteoarthritis: A Comparison of the Cathepsin K Inhibitor Miv-711 Phase 2a MRI Knee Joint Data and KL-Matched 5577 Knee Control Data from the Osteoarthritis Initiative [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-potential-clinical-relevance-of-imaging-biomarker-data-from-short-term-interventional-trials-in-osteoarthritis-a-comparison-of-the-cathepsin-k-inhibitor-miv-711-phase-2a-mri-knee-joint-data-and-k/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-potential-clinical-relevance-of-imaging-biomarker-data-from-short-term-interventional-trials-in-osteoarthritis-a-comparison-of-the-cathepsin-k-inhibitor-miv-711-phase-2a-mri-knee-joint-data-and-k/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology